South Korea · Delayed Price · Currency is KRW DK Life Science Statistics
Total Valuation
DK Life Science has a market cap or net worth of KRW 71.00 billion. The enterprise value is 100.48 billion.
| Market Cap | 71.00B |
| Enterprise Value | 100.48B |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
DK Life Science has 31.98 million shares outstanding. The number of shares has increased by 0.90% in one year.
| Current Share Class | 31.98M |
| Shares Outstanding | 31.98M |
| Shares Change (YoY) | +0.90% |
| Shares Change (QoQ) | -0.86% |
| Owned by Insiders (%) | 15.31% |
| Owned by Institutions (%) | 4.52% |
| Float | 11.99M |
Valuation Ratios
The trailing PE ratio is 14.32.
| PE Ratio | 14.32 |
| Forward PE | n/a |
| PS Ratio | 0.60 |
| PB Ratio | 0.54 |
| P/TBV Ratio | 0.55 |
| P/FCF Ratio | 58.47 |
| P/OCF Ratio | 8.47 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 5.99, with an EV/FCF ratio of 82.73.
| EV / Earnings | 20.20 |
| EV / Sales | 0.85 |
| EV / EBITDA | 5.99 |
| EV / EBIT | 9.86 |
| EV / FCF | 82.73 |
Financial Position
The company has a current ratio of 1.73, with a Debt / Equity ratio of 0.28.
| Current Ratio | 1.73 |
| Quick Ratio | 1.33 |
| Debt / Equity | 0.28 |
| Debt / EBITDA | 2.25 |
| Debt / FCF | 31.12 |
| Interest Coverage | 2.91 |
Financial Efficiency
Return on equity (ROE) is 3.82% and return on invested capital (ROIC) is 4.93%.
| Return on Equity (ROE) | 3.82% |
| Return on Assets (ROA) | 3.01% |
| Return on Invested Capital (ROIC) | 4.93% |
| Return on Capital Employed (ROCE) | 7.38% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 1.18B |
| Profits Per Employee | 49.75M |
| Employee Count | 100 |
| Asset Turnover | 0.56 |
| Inventory Turnover | 2.85 |
Taxes
In the past 12 months, DK Life Science has paid 1.32 billion in taxes.
| Income Tax | 1.32B |
| Effective Tax Rate | 20.92% |
Stock Price Statistics
The stock price has decreased by -48.49% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -48.49% |
| 50-Day Moving Average | 2,347.80 |
| 200-Day Moving Average | 3,116.53 |
| Relative Strength Index (RSI) | 38.65 |
| Average Volume (20 Days) | 51,003 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, DK Life Science had revenue of KRW 117.75 billion and earned 4.97 billion in profits. Earnings per share was 155.07.
| Revenue | 117.75B |
| Gross Profit | 29.78B |
| Operating Income | 10.19B |
| Pretax Income | 6.29B |
| Net Income | 4.97B |
| EBITDA | 16.77B |
| EBIT | 10.19B |
| Earnings Per Share (EPS) | 155.07 |
Balance Sheet
The company has 8.32 billion in cash and 37.79 billion in debt, with a net cash position of -29.47 billion or -921.42 per share.
| Cash & Cash Equivalents | 8.32B |
| Total Debt | 37.79B |
| Net Cash | -29.47B |
| Net Cash Per Share | -921.42 |
| Equity (Book Value) | 132.70B |
| Book Value Per Share | 4,184.91 |
| Working Capital | 57.91B |
Cash Flow
In the last 12 months, operating cash flow was 8.38 billion and capital expenditures -7.16 billion, giving a free cash flow of 1.21 billion.
| Operating Cash Flow | 8.38B |
| Capital Expenditures | -7.16B |
| Depreciation & Amortization | 6.58B |
| Net Borrowing | -3.34B |
| Free Cash Flow | 1.21B |
| FCF Per Share | 37.97 |
Margins
Gross margin is 25.29%, with operating and profit margins of 8.65% and 4.23%.
| Gross Margin | 25.29% |
| Operating Margin | 8.65% |
| Pretax Margin | 5.34% |
| Profit Margin | 4.23% |
| EBITDA Margin | 14.24% |
| EBIT Margin | 8.65% |
| FCF Margin | 1.03% |
Dividends & Yields
DK Life Science does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.90% |
| Shareholder Yield | -0.90% |
| Earnings Yield | 7.01% |
| FCF Yield | 1.71% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on August 7, 2025. It was a forward split with a ratio of 2.
| Last Split Date | Aug 7, 2025 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
DK Life Science has an Altman Z-Score of 2.14 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.14 |
| Piotroski F-Score | 6 |